Arsenic trioxide induces apoptosis of glucocorticoid-resistant acute lymphoblastic leukemia CEM-C1 cells
Tóm tắt
To explore the effects of arsenic trioxide (ATO) on the apoptosis of glucocorticoid (GC)-resistant T-acute lymphoblastic leukemia (ALL) CEM-C1 cells and its possible mechanisms. Different concentrations of ATO (0.25 μmol/L-5 μmol/L) were used to induce the apoptosis of CEM-C1 cells. The inhibition rate of cell proliferation and apoptosis were detected by MTT test, Annexin V-FITC/PI flow cytometry and optical microscopy, respectively. RT-PCR was applied to semi-quantitatively analyze the mRNA expression of pro-apoptotic proteins (Bad and PDCD4) and anti-apoptotic proteins (XIAP and MCL-1) induced by different concentrations of ATO at different time points. ATO could inhibit proliferation and induce apoptosis of CEM-C1 cells at a concentration and time dependent manner. Low-dose ATO mildly inhibited the proliferation of CEM-C1 cells while higher concentrations (1 μmol/L and 5 μmol/L) had strong anti-tumor effect with the inhibiting rates of 40.07±7.98% and 88.67±2.88%, respectively. Annexin V-FITC/PI flow cytometry showed that the apoptotic rates of CEM-C1 cells were significantly increased after 48 hours treatment of different concentrations of ATO. RT-PCR demonstrated up-regulated mRNA expression of pro-apoptotic protein Bad and PDCD4 but down-regulated mRNA expression of anti-apoptotic protein XIAP when CEM-C1 cells were treated with different concentrations of ATO at different time points. The MCL-1 mRNA expression was down-regulated only after the treatment of 5 μmol/L ATO. ATO can inhibit cell proliferation and induce cell apoptosis in GC-resistant CEM-C1 cells. The molecular mechanisms might involve the increased mRNA expression of pro-apoptotic protein Bad and PDCD-4, and rapid down-regulation of XIAP mRNA expression.
Tài liệu tham khảo
Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster [J]. Leukemia 2000; 14:2205–2222.
Park JH, Kim EJ, Jang HY, et al. Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases [J]. Oncol Rep 2008; 20:379–384.
Lee C, Lin Y, Huang M, et al. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo [J]. Leuk Lymphoma 2006; 47:521–529.
Sahara N, Takeshita A, Kobayashi M, et al. Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway [J]. Leuk Lymphoma 2004; 45:987–995.
Cowburn AS, Cadwallader KA, Reed BJ, et al. Role of PI3-kinase-dependent Bad phosphorylation and altered transcription in cytokine-mediated neutrophil survival [J]. Blood 2002; 100: 2607–2616.
Hasegawa T, Suzuki K, Sakamoto C, et al. Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia [J]. Blood 2003; 101:1164–1171.
Ozpolat B, Akar U, Steiner M, et al. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells [J]. Mol Cancer Res 2007; 5: 95–108.
Yang Q, Gao YM, Bing LJ, et al. Role of Npm1 in proliferation, apoptosis and differentiation of neural stem cells [J]. J Neurol Sci 2008; 266:131–137.
Liu HT, Li Q, Guo X. Clinical, morphologic and cytogenetic characteristics of childhood acute lymphoblastic leukemia: a comparison between prednisone poor responder and good responder [J]. Chin J Pedi (in Chinese) 2007; 45:865–867.
Tabellini G, Tazzari PL, Bortul R, et al. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukemias [J]. Br J Haematol 2005; 130:716–725.
Lunghi P, Tabilio A, Lo-Coco F, et al. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells [J]. Leukemia 2005; 19:234–244.
Kerbauy DM, Lesnikov V, Abbasi N, et al. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs) [J]. Blood 2005; 106: 3917–3925.
Dolniak B, Katsoulidis E, Carayol N, et al. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2 [J]. J Biol Chem 2008; 283:12034–2042.
Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family [J]. EMBO 2006; 7: 988–994.
Akyurek N, Ren Y, Rassidakis GZ, et al. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas [J]. Cancer 2006; 107:1844–1851.
Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets [J]. Apoptosis 2007; 12:1543–1568.
Hilliard A, Hilliard B, Zheng SJ, et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4 [J]. J Immunol 2006; 177:8095–8102.
Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies [J]. J Clin Oncol 2005; 23:2396–2410.